Join Now

Category Archives: BioUtah News

ARUP Healthcare Advisory Services Wins a Third ASCP Choosing Wisely Champion Award

ARUP Healthcare Advisory Services Wins a Third ASCP Choosing Wisely Champion Award

| Tagged | Comments Off on ARUP Healthcare Advisory Services Wins a Third ASCP Choosing Wisely Champion Award

Merit Medical Launches Expanded Maestro® Microcatheter Line

New multipurpose microcatheter length complements Merit’s radial-first legacy

| Tagged | Comments Off on Merit Medical Launches Expanded Maestro® Microcatheter Line

GE HealthCare imaging CEO Jan Makela talks Mayo Clinic partnership

GE and Mayo Clinic plan to collaborate on imaging, artificial intelligence and cancer treatment.

| Tagged | Comments Off on GE HealthCare imaging CEO Jan Makela talks Mayo Clinic partnership

US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix

US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix

| Tagged | Comments Off on US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix

National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS

Funding to Support Research and Expanded Access of Investigational Drug in ALS SALT LAKE CITY, Oct. 05, 2023 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN), through its wholly owned subsidiary Clene Nanomedicine Inc. in collaboration with Columbia University and Synapticure, has been awarded a four-year grant totaling $45.1 million from the National Institute of Neurological […]

| Comments Off on National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS

Owlet Commits Critical Support To Parents and Researchers On A Mission To End SIDS

LEHI, Utah–(BUSINESS WIRE)– Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), a pioneer of smart baby monitoring, is on a mission to raise critical funds for research that could bring an end to sudden infant death syndrome (SIDS). Owlet is partnering in this effort with Dr. Carmel Harrington, Honorary Research Fellow at Sydney Children’s Hospital […]

| Comments Off on Owlet Commits Critical Support To Parents and Researchers On A Mission To End SIDS

New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood

New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood

| Tagged | Comments Off on New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood

Medical Technology Company Focused on Vessel Preparation, Dilation, And Treatment Delivery Secures Series B Funding

Medical Technology Company Focused on Vessel Preparation, Dilation, And Treatment Delivery Secures Series B Funding

| Tagged | Comments Off on Medical Technology Company Focused on Vessel Preparation, Dilation, And Treatment Delivery Secures Series B Funding

Biomerics Announces Completion of 100,000 sq. ft. Expansion of Brooklyn Park, MN, Facility

Biomerics Announces Completion of 100,000 sq. ft. Expansion of Brooklyn Park, MN, Facility

| Tagged | Comments Off on Biomerics Announces Completion of 100,000 sq. ft. Expansion of Brooklyn Park, MN, Facility

Audio-based Detection of Anxiety and Depression via Vocal Biomarkers

Audio-based Detection of Anxiety and Depression via Vocal Biomarkers

| Tagged | Comments Off on Audio-based Detection of Anxiety and Depression via Vocal Biomarkers

bioMérieux submits Dual 510(k) and CLIA-waiver application to FDA for the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel

Marcy-l’Étoile (France), September 22nd, 2023 – bioMérieux, a world leader in the field of in vitro diagnostics, has submitted the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel to U.S. Food and Drug Administration (FDA) for a dual 510(k) clearance and CLIA1-waiver. This panel is already CE-marked (IVDD2).

| Tagged | Comments Off on bioMérieux submits Dual 510(k) and CLIA-waiver application to FDA for the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel

Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials

Myriad can conduct prospective clinical trials using Illumina’s TruSight Oncology Comprehensive Investigational Use Only test SALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two key milestones in its strategic partnership with Illumina Inc. (NASDAQ: ILMN), a global leader in […]

| Comments Off on Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials